Bristol Myers, bluebird to resubmit cancer therapy filing as FDA declines review

Bristol Myers Squibb Co said on Wednesday it planned to resubmit its application for an experimental multiple myeloma therapy by the end of July after the U.S. drug regulator declined to review the treatment as it sought more information.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news